Ruveyda Ayasun (Rüveyda Ayasun)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Top Venues

Future virology

JCO oncology practice

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Ibrahim Halil Sahin, Turcin Saridogan, Ruveyda Ayasun, Masood Pasha Syed, Vikram Gorantla, Monica Malhotra, Roby Thomas, John Rhee, Janie Y Zhang, Dennis J Hsu, Aatur D Singhi, Anwaar Saeed
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine. JCO oncology practice (2024)
Justine Habault, Jeffrey A Schneider, Susan Ha, Rachel Ruoff, Luiza D Doro Pereira, Joseph Puccini, Michela Ranieri, Ruveyda Ayasun, Jiehui Deng, Amanda C Kasper, Dafna Bar-Sagi, Kwok-Kin Wong, Amina Zoubeidi, Frank Claessens, David R Wise, Susan K Logan, Kent Kirshenbaum, Michael J Garabedian
A multivalent peptoid conjugate modulates androgen receptor transcriptional activity to inhibit therapy-resistant prostate cancer. Molecular cancer therapeutics (2023)
Ruveyda Ayasun, Muhammet Ozer, Ilyas Sahin
The Role of HER2 Status in the Biliary Tract Cancers. Cancers 15 (9) (2023)
Ruveyda Ayasun, Muhammet Ozer, Ilyas Sahin
The Role of HER2 Status in the Biliary Tract Cancers. Cancers 15 (9) (2023)
William E Damsky, Alice Wang, Daniel J Kim, Bryan D Young, Katelyn Singh, Michael J Murphy, Joseph Daccache, Abigale Clark, Ruveyda Ayasun, Changwan Ryu, Meaghan K McGeary, Ian D Odell, Ramesh Fazzone-Chettiar, Darko Pucar, Robert J Homer, Mridu Gulati, Edward J Miller, Marcus W Bosenberg, Richard A Flavell, Brett A King
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature communications 13 (1) (2022)
Ruveyda Ayasun, Deniz Can Guven, Ibrahim Gullu
A novel agnostic tumor: NTRKoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (4) (2021)
Emre Yekedüz, Ruveyda Ayasun, Elif Berna Koksoy, Gungor Utkan, Yuksel Urun, Hakan Akbulut
mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors. Future virology (2021)